Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy



Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using Virtual Reality Therapy

A novel treatment, a digital therapeutics software solution for Chronic Pain (DTxP), has shown statistically significant benefit over passive (placebo)control and standard care interventions for fear of movement, patient clinical global impression of change (PGIC) and quality of life in adult patients with chronic low back pain (CLBP). Results from Orion Corporation’s pilot study ‘VIRPI were announced at the IASP 2021 Virtual World Congress On Pain.

Results from the ‘VIRPI’ study in patients with CLBP showed that TSK score (Tampa Scale for Kinesiophobia assessing fear of movement) was significantly reduced at the end-of-intervention (EOI) for DTxP. Primary analysis for the difference between DTxP and passive control at EOI was statistically significant: -4.7 points (-9.4 to -0.1, p=0.046) and increased when compared to standard care -6.1 (-10.9 to -1.3, p=0.014). Patient clinical global impression of change (PGIC), which reflects a patient's belief about the efficacy of the treatment, and their quality of life (QoL) also reached a statistically significant difference at EOI in comparison to passive control and standard care groups.

Non-statistically significant improvements were reported with DTxP for Oswestry Disability Index (ODI), pain interference (Patient-Reported Outcomes Information System: PROMIS), and pain intensity (PROMIS-Numerical Rating Scale). Adverse effects appeared acceptable and similar to passive control.

“There is an unmet need for novel therapies in the treatment of chronic pain. The currently available treatments may provide suboptimal efficacy and tolerability to certain patients. Digital therapeutics (DTx) is a new and rapidly evolving treatment paradigm, also for pain. We are exploring different solutions, such as this DTxP, for the future of pain care”, says Sammeli Liikkanen, Director of Digital Medicine at Orion Corporation.

“Cognitive Behavioral Therapy (CBT) is scientifically sound, effective and a recommended method to improve the self-management of chronic pain. For many suffering with difficult pain and disability, it is one option to reverse the decline in loss of function, and help people return to valued goals and activities. However, the access to qualified practitioners is very limited and getting smaller as the number of people with pain grows. DTx solutions operating within a CBT framework could bring new treatment options, potentially more powerful treatment options, to a larger population of patients”, says Christopher Eccleston, Professor of Pain Research at University of Bath.

Orion is looking for a partner to further develop and commercialise Orion’s digital therapeutics software solution for Chronic Pain.

Orion’s digital therapeutics software solution for Chronic Pain (DTxP)

Orion’s DTxP, aimed to be a software as medical device (SaMD), is built for virtual reality (VR) devices to provide an immersive gamified therapeutic treatment program for the chronic pain patients. The product contains behaviour change advice and instruction, presented as modules that can be tailored to the patients’ needs. The product is designed to be flexible and to be used as a part of multiple different treatment approaches. It also provides objective data to patients and treating healthcare professionals. As an example, gamified physical movements with proven safety targeted to encourage movement can lead one to overcome the fear of movement, and so increase activity. The software has been developed by Orion in close collaboration with external scientific advisor Christopher Eccleston from University of Bath, and technology partner Healthware Group, with support from Business Finland.

The VIRPI trial design

The VIRPI trial is a prospective, randomised, double-blind, 3-arm parallel group comparison of DTxP, passive control (a placebo “sham” running on VR specifically developed for this purpose) and an open standard care arm evaluating the safety and efficacy of DTxP in patients with chronic low back pain (CLBP). Inclusion criteria were low back pain for at least 3 months, average pain intensity of ≥4 over the past week on a 0–10 Numerical Rating Scale (NRS), Oswestry Disability Index (ODI) of ≥26%, and medium (34-41) or high (42-68) Tampa Scale for Kinesiophobia (TSK) score.

A total of 42 patients were randomised to receive DTxP (14), passive control (17) or standard care (11). Participants undertook DTxP or passive control for 15-60 minutes at a time, on 5 or more days per week up to the end-of-intervention (EOI). EOI was defined as the completion of 30 modules of DTxP or passive control, which took 6-8 weeks. Approximately 3 months after the EOI, information about pain status, disability, kinesiophobia, overall status and any adverse event (AE) were collected as follow-up data. Quality of life (QoL) was evaluated with the EQ-5D-5L questionnaire. The third group, randomly assigned to the standard care arm, visited the site for screening on Day 1 and 6-8 weeks after randomisation. After week 9 follow-up visit, the participants were re-randomised between DTxP and passive control for the next 6-8 weeks, followed by a 3-month follow-up period.

Contact person:

Sammeli Liikkanen, Director of Digital Medicine, Orion Corporation
tel. +358 50 966 7466

IASP 2021 Virtual World Congress On Pain website:

Orion Corporation
Orionintie 1A, FI-02200 Espoo, Finland

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire


AuctionAuction resultsAuction date2021-06-15Maturity2024Tendered volume, SEK mln1000 +/- 1000Offered volume, SEK mln137Volume bought, SEK mln137Number of bids3Number of accepted bids3 QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln0000Volume bought, SEK mln0000Number of bids0000Number of accepted bids0000Average DM----Lowest accepted DM----Highest DM----Accepted at lowest DM---- QuarterQuarter 1Quarter 2Quarter 3Quarter 4Offered volume, SEK mln013070Volume bought, SEK mln013070Number of bids0210Number of accepted bids0210Average DM--5-2-Lowest accepted DM--5-2-Highest DM--5-2-Accepted at lowest DM-100.00%100.00%-

Karolinska Development’s portfolio company Modus Therapeutics and Imperial College London to conduct clinical study of sevuparin in severe malaria15.6.2021 11:24:44 CEST | Press release

STOCKHOLM, SWEDEN – June 15, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics has entered into a collaboration agreement with Imperial College London to evaluate the effect of its drug candidate sevuparin in patients with severe malaria. Sevuparin is currently being developed in the indication sepsis/septic shock, a condition that bears resemblance to the systemic inflammatory reaction that occurs in connection with severe malaria infection. Malaria causes more than 400,000 deaths per year and the need for new and effective drugs is therefore great. Severe malaria continues to be a medical challenge in several parts of the world. The disease often affects children and the need for effective drugs is great as malaria can induce a systemic inflammatory reaction leading to multi-organ failure, a reaction similar to that seen in sepsis/septic shock. The purpose of the collaboration announced today is to conduct a clinica

Karolinska Developments portföljbolag Modus Therapeutics och Imperial College London planerar klinisk studie av sevuparin mot svår malaria15.6.2021 11:24:44 CEST | Pressemelding

STOCKHOLM, SVERIGE 15 juni 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics och Imperial College London har ingått ett samarbetsavtal i syfte att utvärdera effekten av bolagets läkemedelskandidat sevuparin i patienter med svår malaria. Sevuparin utvecklas sedan tidigare inom indikationen sepsis/septisk chock, ett tillstånd som bär vissa likheter med den systemiska inflammationsreaktion som uppstår i samband med svår malariainfektion. Malaria orsakar fler än 400 000 dödsfall per år och behovet av nya och effektiva läkemedel är därför stort. Svår malaria utgör fortsatt en medicinsk utmaning i flera delar av världen. Sjukdomen drabbar ofta barn och behovet av effektiva läkemedel är stort eftersom malaria kan inducera en systemisk inflammatorisk reaktion som leder till multiorgansvikt, en reaktion som liknar den man ser vid sepsis/septisk chock. Syftet med det samarbete som annonseras idag är att genomföra en klinisk studie för a


Bid date, 2021-06-15Auction date2021-06-15Settlement date2021-06-16Maturity Date2021-06-23Nominal amount484 billion SEKInterest rate, %0.00Bid times09.30-10.00 (CET/CEST) on the Bid dateConfirmation of bids to e-mailrbcert@riksbank.seThe lowest accepted bid volume1 million SEKThe highest accepted bid volume484 billion SEKAllocation Time10.15 (CET/CEST) on the Bid dateProjected minimum liquidity surplus during the term968 billion SEKExpected excess liquidity at full allotment484 billion SEK Stockholm, 2021-06-15

Klövern kommer att sammankalla en extra bolagsstämma enligt begäran från Corem15.6.2021 09:06:03 CEST | Pressemelding

En extra bolagsstämma kommer att hållas i Klövern AB (publ) (”Klövern”) den 9 juli 2021 för val av ny styrelse i enlighet med begäran från Corem. Kallelse utfärdas separat. Corem Property Group AB (publ) (”Corem”) lämnade den 29 mars 2021 ett offentligt uppköpserbjudande till aktieägarna i Klövern. Corem förklarade idag erbjudandet ovillkorat och förlängde acceptfristen till den 23 juni 2021. Corem kontrollerar cirka 89,1 procent av de utestående aktierna och cirka 90,8 procent av rösterna i Klövern. Klövern AB (publ) För ytterligare information, vänligen kontakta: Pia Gideon, styrelseordförande i Klövern Tel: 070-546 71 00 Klövern är ett fastighetsbolag som med närhet och engagemang erbjuder attraktiva lokaler i tillväxtregioner. Klövern är noterat på Nasdaq Stockholm. Ytterligare information finns på Klövern AB (publ), Bredgränd 4, 111 30 Stockholm. Tel: 010-482 70 00, Email: Detta pressmeddelande har offentliggjorts på svenska och engelska. Vid en ev

Klövern will convene an Extraordinary General Meeting in accordance with a request from Corem15.6.2021 09:06:03 CEST | Press release

An Extraordinary General Meeting will be held in Klövern AB (publ) (”Klövern”) on 9 July 2021 to elect a new Board of Directors in accordance with a request from Corem. A notice will be issued separately. On 29 March 2021, Corem Property Group AB (publ) (”Corem”) announced a public offer to the shareholders of Klövern. Today, Corem declared the offer unconditional and extended the acceptance period to 23 June 2021. Corem controls approximately 89.1 percent of the outstanding shares and approximately 90.8 percent of the votes in Klövern. Klövern AB (publ) For further information, pleasecontact: Pia Gideon, Chairman of the Board of Directors in Klövern Phone: +46 70 546 71 00 Klövern is a real estate company committed to working closely with customers to offer them attractive premises in growth regions. Klövern is listed on Nasdaq Stockholm. For further information, see Klövern AB (publ), Bredgränd 4, 111 30 Stockholm. Phone: +46 10 482 70 00. Email: This